Bio-Rad Laboratories Stockholders Approve Directors and Governance Items
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Bio-Rad Laboratories ( (BIO) ).
At its April 21, 2026 annual meeting of stockholders, Bio-Rad Laboratories, Inc. reported that all nominated directors were elected by majorities within their respective classes of common stock, reinforcing continuity in the company’s board leadership and governance structure. Stockholders also ratified the appointment of KPMG LLP as independent auditor for fiscal 2026 and approved, on an advisory basis, the executive compensation program, signaling broad investor support for current financial oversight and pay practices.
Investors further backed an amended 2017 Incentive Award Plan, indicating continued alignment with the company’s long-term compensation and incentive framework for management and employees. However, a stockholder proposal to alter Bio-Rad’s dual class capital structure failed to gain majority support, preserving the existing voting power balance between Class A and Class B shares and maintaining the current control dynamics for the company’s stakeholders.
The most recent analyst rating on (BIO) stock is a Hold with a $300.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.
Spark’s Take on BIO Stock
According to Spark, TipRanks’ AI Analyst, BIO is a Neutral.
The score is anchored by solid fundamentals—conservative leverage and consistently positive free cash flow—tempered by volatile reported earnings. Technicals are a meaningful headwind with clear downside momentum. Valuation is a support (low P/E), while the latest call adds moderate confidence via steady 2026 margin/FCF outlook but highlights near-term execution and segment headwinds.
To see Spark’s full report on BIO stock, click here.
More about Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. is a life science research and clinical diagnostics company that develops, manufactures, and markets a broad range of products and systems used for biological research and healthcare testing. The company serves academic, pharmaceutical, biotechnology, and clinical laboratory customers globally through its diversified diagnostic and research-focused portfolio.
Average Trading Volume: 294,610
Technical Sentiment Signal: Sell
Current Market Cap: $7.59B
Find detailed analytics on BIO stock on TipRanks’ Stock Analysis page.
